GlassScriptPhysician profile
Jess F Armor
NPI 1922059666
$6,221.97
in general payments reported to CMS, 2019-2025
42 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $230 · 2021: $112 · 2022: $1,258 · 2023: $1,095 · 2024: $1,578 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,283 · Food and Beverage: $1,562 · Education: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,282.65 |
| Food and Beverage | $1,561.52 |
| Education | $386.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,158.44 | 2019-2025 | |
| Pfizer INC. | $477.07 | 2019-2025 | |
| Genentech USA, INC. | $264.19 | 2019-2025 | Lunsumio, Venclexta, Phesgo |
| Astrazeneca Pharmaceuticals LP | $248.65 | 2019-2025 | Lynparza |
| Astellas Pharma US INC | $219.59 | 2019-2025 | Padcev |
| Beone Medicines USA, INC. | $190.41 | 2025 | Brukinsa |
| Merck Sharp & Dohme LLC | $172.73 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $161.22 | 2019-2024 | Opdivo |
| Array Biopharma INC | $140.19 | 2022-2023 | Lorbrena, Xalkori, Mektovi |
| Celgene Corporation | $129.02 | 2022-2023 | Reblozyl, Opdualag |
| Janssen Biotech, INC. | $99.37 | 2019-2023 | Darzalex |
| Abbvie INC. | $80.35 | 2023-2024 | Venclexta |
| Beigene USA, INC. | $78.01 | 2020-2025 | Brukinsa |
| Gilead Sciences, INC. | $68.32 | 2019-2024 | Trodelvy |
| Emd Serono, INC. | $66.89 | 2020-2024 |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jess Armor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.